Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

4 Weeks Repeated Oral Dose Toxicity Studies with LMK02-Jangwonhwan in SD Rats

LMK02의 Sprague-Dawley 랫드를 이용한 4 주간 반복 경구투여 DRF 독성시험

  • Lyu, Yeoung-Su (Department of Neuropsychiatry, College of Oriental Medicine, Wonkwang University) ;
  • Kim, Ji-Hwon (Department of Neuropsychiatry, College of Oriental Medicine, Wonkwang University) ;
  • Park, Hyun-Je (Herbal Medicines Unit, Yuhan Research Institute) ;
  • Yi, Kyung-Hee (Department of Pediatrics, College of Medicine, Wonkwang University, Sanbon Medical Center) ;
  • Lee, Jong-Hwa (Department of Pediatrics, College of Medicine, Wonkwang University, Sanbon Medical Center) ;
  • Kang, Hyung-Won (Department of Neuropsychiatry, College of Oriental Medicine, Wonkwang University)
  • 류영수 (원광대학교 한의과대학 한방신경정신과교실) ;
  • 김지훤 (원광대학교 한의과대학 한방신경정신과교실) ;
  • 박현제 (유한양행 중앙연구소 천연물신약유닛트) ;
  • 이경희 (원광대학교 산본병원 소아과학교실) ;
  • 이종화 (원광대학교 산본병원 소아과학교실) ;
  • 강형원 (원광대학교 한의과대학 한방신경정신과교실)
  • Received : 2010.10.18
  • Accepted : 2010.12.01
  • Published : 2010.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

The oriental medicine Jangwonhwan, which is a boiled extract of 12 medicinal herbs/mushroom, has been prescribed for patients with cognitive dysfunction and it is originally from the Korean medical text, DonguiBogam(amnesia chapter). Recently, a modified recipe of Jangwonhwan (LMK02-Jangwonhwan) consisting of seven medicinal plants/mushroom, was shown to reduce ${\beta}$-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease. The toxicity of LMK02 was investigated in SD rats by oral repeated adminstration for 4 weeks and we tried to determine test does for 13 weeks repeated study. Quality control of tablet form of LMK02 was established by estimating indicative components, Ginsenoside Rg3 of Red Ginseng and Decursin of Angelicagigas Nakai. The toxicity of LMK02 was investigated in 6 weeks old specific pathogen free (SPF) Sprageu-Dawley rats by oral administration. Each test group were consist of 5 male and 5 female and they received doses of 500, 1,000 and 2,000 mg/kg/day of test substance for 4 weeks. The clinical signs, death rate, body weight, food consumption, ophthalmic examination, urinalysis, hematological and serum biochemistry, organ weight and pathological changes were examined and compared with those of control group. Urinalysis : We observed increase of PRO(p<0.01), SG(p<0.01) in female rats of 1,000 mg/kg/day and 2,000 mg/kg/day(p<0.01). Also, we observed increase of pH and KET in female rats of 1,000 mg/kg/day(p<0.05) and of 2,000 mg/kg/day(p<0.01). WBC in female rats in 1,000 mg/kg/day and 2,000 mg/kg/day were on increase. Hematological test : We observed increase of MCV in male rats of 250 mg/kg/day. (p<0.05) Serum biochemistry test : We found increase of CHO in female rats of 2,000 mg/kg/day(p<0.05). During the experimental period, there were no animals dead or moribund. There were no treatment related changes of general symptom, food and water consumption, organ weight and autopsy According to the results of 4-week repeated dose range finding study, the highest dose was established as 1000 mg/kg for 13-week repeated dose toxicity study and we determined to put 2 more groups by common ratio two.

Keywords

References

  1. 한설희. 알츠하이머병의 새로운 약물치료. J Korean Med Assoc. 52(11):1059-1068, 2009. https://doi.org/10.5124/jkma.2009.52.11.1059
  2. Arnold, S.E., Lee, E.B., Moberg, P.J., Stutzbach, L., Kazi, H., Han, L.Y., Lee, V.M., Trojanowski, J.Q. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disea. Ann Neurol. 67(4):462-469, 2010. https://doi.org/10.1002/ana.21910
  3. Rebeck, G.W., Hoe, H.S., Moussa, C.E. Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem. 285(10): 7440-7446, 2010. https://doi.org/10.1074/jbc.M109.083915
  4. Lee, K.W., Kim, J.B., Seo, J.S., Kim, T.K., Im, J.Y., Baek, I.S., Kim, K.S., Lee, J.K., Han, P.L. Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. J Neurochem. 108(1):165-175, 2009. https://doi.org/10.1111/j.1471-4159.2008.05769.x
  5. Iacopino, A.M., Christakos, S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A. 87(11):4078-4082, 1990. https://doi.org/10.1073/pnas.87.11.4078
  6. Yamamoto-Sasaki, M., Ozawa, H., Saito, T., Rösler, M., Riederer, P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 824(2):300-303, 1999. https://doi.org/10.1016/S0006-8993(99)01220-2
  7. Greilberger, J., Koidl, C., Greilberger, M., Lamprecht, M., Schroecksnadel, K., Leblhuber, F., Fuchs, D., Oettl, K. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res. 42(7):633-638, 2008. https://doi.org/10.1080/10715760802255764
  8. Ghosh, A.K., Hong, L., Tang, J. Beta-secretase as a therapeutic target for inhibitor drugs. Curr Med Chem. 9(11):1135-1144, 2002. https://doi.org/10.2174/0929867023370149
  9. Imbimbo, B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 8(1):54-61, 2008. https://doi.org/10.2174/156802608783334015
  10. 許俊. 東醫寶鑑. 서울, 法仁文化社, pp 189-191, 1999.
  11. 강형원, 김상태, 손형진, 한평림, 조형권, 이영재, 류영수. LMK02의 품질규격화와 $A\beta$ oligomer에 의해 유도된 흰쥐해마 H19-7 세포주에 미치는 항치매 효과. 동의생리병리학회지 23(2):397-404, 2009.
  12. Seo, J.S., Yun, J.H., Baek, I.S., Leem, Y.H., Kang, H.W., Cho, H.K., Lyu, Y.S., Son, H.J., Han, P.L. Oriental medicine Jangwonhwan reduces Abeta(1-42) level and beta-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease. J Ethnopharmacol. 128(1):206-212, 2010. https://doi.org/10.1016/j.jep.2010.01.014
  13. Korea Food and Drug Administration. Toxicity Test Guidelines for Safety Evaluation of Drugs, Notification. 60, 2005.
  14. Korea Food and Drug Administration. Good Laboratory Practice Regulation For Nonclinical Laboratory Studies, Notification No. 2005-79, Toxicity Test Guidelines for Safety Evaluation of Drugs.
  15. OECD Guidelines for the Testing of Chemicals, Acute Oral Toxicity: Up-and-Down-Procedure (UDP). 425, 2006.
  16. 강형원, 권영미, 이상원, 김지훤, 이효경, 장현호, 박보라, 류영수. Sprague-Dawley 랫드를 이용한 Up & Down 법(UDP)에 의한 LMK02의 단회 경구투여 독성시험. 동의신경정신과학회지 21(3):97-93, 2010.
  17. Acute Oral Toxicity (OECD Test Guideline 425) Statistical Programme (AOT 425 StatPgm). Version:1.0, 2001. [http://www.oecd.org/oecd/pages/home/displaygeneral/0 ,3380,EN-document-524-nodirectorate-no-24-6775-8,FF.html]
  18. 조맹제. 국내 치매 노인 유병율 현황과 위험요인. 서울. 보건복지포럼. 156: 43-48, 2009.
  19. Jellinger, K.A. Clinicopathological analysis of dementia disorders in the elderly. J. Alzheimers Dis. 9(3):61-70, 2006. https://doi.org/10.3233/JAD-2006-9S308
  20. Sultana, R., Perluigi, M., Butterfield, D.A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD, role of Abeta in pathogenesis. Acta Neuropathol. 118(1):131-150, 2009. https://doi.org/10.1007/s00401-009-0517-0
  21. 김건진, 정대규. 壯元丹이 CT105 및 $A\beta$로 유발된 치매병태 모델에 미치는 영향. 동의신경정신과학회지 17(2):91-122, 2006.
  22. 강형원, 김상태, 이종화, 김태헌, 손형진, 한평림, 류영수. 壯元丸加減方수추출물이 아밀로이드 전구단백질로 유도된 생쥐의 신경아세포주에서의 항치매 효과. 동의신경정신과학회지 18(2):13-24, 2007.
  23. 전국한의과대학 공동교재편찬위원회 편저. 본초학. 서울, 영림사, pp 233-234, 345-347, 532-533, 563-564, 573-576, 630-633, 645-647, 2010.